Dmitry Gabrilovich
Overview
Explore the profile of Dmitry Gabrilovich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
5075
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trizzino M, Zucco A, Deliard S, Wang F, Barbieri E, Veglia F, et al.
Sci Adv
. 2021 Feb;
7(3).
PMID: 33523892
Monocytes and monocyte-derived macrophages originate through a multistep differentiation process. First, hematopoietic stem cells generate lineage-restricted progenitors that eventually develop into peripheral, postmitotic monocytes. Second, blood-circulating monocytes undergo differentiation into...
2.
Hao X, Zhao B, Zhou W, Liu H, Fukumoto T, Gabrilovich D, et al.
iScience
. 2021 Jan;
24(1):102016.
PMID: 33490922
Therapy-induced senescence-associated secretory phenotype (SASP) correlates with overcoming resistance to immune checkpoint blockade (ICB). Intrinsic resistance to ICB is a major clinical challenge. For example, ovarian cancer is largely resistant...
3.
Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, et al.
Nat Commun
. 2021 Jan;
12(1):346.
PMID: 33436641
Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse melanoma model by...
4.
Hashimoto A, Fukumoto T, Zhang R, Gabrilovich D
Cancer Immunol Immunother
. 2020 May;
69(9):1929-1936.
PMID: 32435850
Myeloid-derived suppressor cells (MDSCs) are widely implicated in negative regulation of immune responses in cancer. Inhibition of class I histone deacetylases (HDAC) with entinostat has anti-MDSC activity. However, as single...
5.
Kumar S, Wilkes D, Samuel N, Blanco M, Nayak A, Alicea-Torres K, et al.
J Clin Invest
. 2018 Oct;
128(11):5095-5109.
PMID: 30295647
Triple-negative breast cancer (TNBC) is particularly aggressive, with enhanced incidence of tumor relapse, resistance to chemotherapy, and metastases. As the mechanistic basis for this aggressive phenotype is unclear, treatment options...
6.
Kugel 3rd C, Douglass S, Webster M, Kaur A, Liu Q, Yin X, et al.
Clin Cancer Res
. 2018 Jun;
24(21):5347-5356.
PMID: 29898988
We have shown that the aged microenvironment increases melanoma metastasis, and decreases response to targeted therapy, and here we queried response to anti-PD1. We analyzed the relationship between age, response...
7.
Veglia F, Perego M, Gabrilovich D
Nat Immunol
. 2018 Jan;
19(2):108-119.
PMID: 29348500
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells generated during a large array of pathologic conditions ranging from cancer to obesity. These cells represent a pathologic state of...
8.
Zhou J, Nefedova Y, Lei A, Gabrilovich D
Semin Immunol
. 2017 Dec;
35:19-28.
PMID: 29254756
Neutrophils and polymorphonucler myeloid-derived suppressor cells (PMN-MDSC) share origin and many morphological and phenotypic features. However, they have different biological role. Neutrophils are one of the major mechanisms of protection...
9.
Tyurina Y, Shrivastava I, Tyurin V, Mao G, Dar H, Watkins S, et al.
Antioxid Redox Signal
. 2017 Aug;
29(13):1333-1358.
PMID: 28835115
Significance: Oxygenated polyunsaturated lipids are known to play multi-functional roles as essential signals coordinating metabolism and physiology. Among them are well-studied eicosanoids and docosanoids that are generated via phospholipase A...
10.
Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al.
Clin Cancer Res
. 2017 Jul;
23(17):5187-5201.
PMID: 28698201
Purpose: Recent advances in immunotherapy highlight the antitumor effects of immune checkpoint inhibition despite a relatively limited subset of patients receiving clinical benefit. The selective class I histone deacetylase inhibitor...